FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134524077> ?p ?o ?g. }

• W3134524077 endingPage "100321" @default.
• W3134524077 startingPage "100321" @default.
• W3134524077 abstract "Abstract Introduction Treatments for Peyronie's disease (PD) include surgical management and collagenase clostridium histolyticum (CCH). Aims To evaluate PD treatment trends after CCH approval and compare clinical outcomes in CCH- and surgery-treated cohorts. Methods Patients newly diagnosed with PD between January 2011 and December 2017 were identified in a U.S. claims database. Cohorts initiating treatment with CCH or surgery between January 2014 and June 2017 were included. Patients were continuously enrolled ≥6 months before and ≥12 months after index date. Post-treatment penile complications and analgesic use were compared 1 year after procedure in propensity score-matched cohorts. Main outcome measures The main outcome measures of this study were treatment patterns, penile complications, and analgesic use. Results In the newly diagnosed PD cohort, 1,609 patients received CCH and 1,555 patients had surgery. Overall CCH or surgery treatment rate/year increased from 9.8% in 2014 to 15.5% in 2017, with &lt;1% receiving verapamil or interferon. Initial treatment ratios of CCH to surgery increased from approximately 1:1 (2014) to 2:1 (2017). In the unmatched CCH (n = 1,227) and surgery (n = 620) cohorts, more (P &lt; .05) surgery-treated patients received analgesics (particularly opioids), oral PD therapies, vacuum erection devices, and phosphodiesterase-5 inhibitors before the index date. After propensity score matching (n = 620/cohort), newly occurring postprocedural complications during the follow-up period were higher in the surgery cohort (25.3% vs 18.4%, P = .003). The surgery cohort had significantly (P &lt; .05) higher rates of erectile dysfunction (65.0% vs 44.8%), penile pain (17.9% vs 8.9%), and penile swelling (8.1% vs 5.2%) and was more likely to be prescribed opioids (93.3% vs 38.9%; P &lt; .0001) or non-steroidal anti-inflammatory drugs (27.0% vs 20.3%; P = .006). Conclusion CCH demonstrated fewer complications and less analgesic use than surgery and was used as the initial therapy for PD twice as often as surgery." @default.
• W3134524077 created "2021-03-15" @default.
• W3134524077 creator A5034673183 @default.
• W3134524077 creator A5043779414 @default.
• W3134524077 creator A5044535901 @default.
• W3134524077 creator A5083719568 @default.
• W3134524077 creator A5084623797 @default.
• W3134524077 date "2021-03-05" @default.
• W3134524077 modified "2023-09-26" @default.
• W3134524077 title "Treatment Patterns and Healthcare Outcomes with Collagenase Clostridium Histolyticum vs Surgery in Peyronie's Disease: A Retrospective Claims Database Analysis" @default.
• W3134524077 cites W1587420189 @default.
• W3134524077 cites W2121656227 @default.
• W3134524077 cites W2151452572 @default.
• W3134524077 cites W2153633032 @default.
• W3134524077 cites W2283148898 @default.
• W3134524077 cites W2795860152 @default.
• W3134524077 cites W2915926595 @default.
• W3134524077 doi "https://doi.org/10.1016/j.esxm.2021.100321" @default.
• W3134524077 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8072160" @default.
• W3134524077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33684795" @default.
• W3134524077 hasPublicationYear "2021" @default.
• W3134524077 type Work @default.
• W3134524077 sameAs 3134524077 @default.
• W3134524077 citedByCount "4" @default.
• W3134524077 countsByYear W31345240772022 @default.
• W3134524077 countsByYear W31345240772023 @default.
• W3134524077 crossrefType "journal-article" @default.
• W3134524077 hasAuthorship W3134524077A5034673183 @default.
• W3134524077 hasAuthorship W3134524077A5043779414 @default.
• W3134524077 hasAuthorship W3134524077A5044535901 @default.
• W3134524077 hasAuthorship W3134524077A5083719568 @default.
• W3134524077 hasAuthorship W3134524077A5084623797 @default.
• W3134524077 hasBestOaLocation W31345240771 @default.
• W3134524077 hasConcept C126322002 @default.
• W3134524077 hasConcept C141071460 @default.
• W3134524077 hasConcept C167135981 @default.
• W3134524077 hasConcept C17923572 @default.
• W3134524077 hasConcept C201903717 @default.
• W3134524077 hasConcept C2779145901 @default.
• W3134524077 hasConcept C2779929075 @default.
• W3134524077 hasConcept C71924100 @default.
• W3134524077 hasConcept C72563966 @default.
• W3134524077 hasConceptScore W3134524077C126322002 @default.
• W3134524077 hasConceptScore W3134524077C141071460 @default.
• W3134524077 hasConceptScore W3134524077C167135981 @default.
• W3134524077 hasConceptScore W3134524077C17923572 @default.
• W3134524077 hasConceptScore W3134524077C201903717 @default.
• W3134524077 hasConceptScore W3134524077C2779145901 @default.
• W3134524077 hasConceptScore W3134524077C2779929075 @default.
• W3134524077 hasConceptScore W3134524077C71924100 @default.
• W3134524077 hasConceptScore W3134524077C72563966 @default.
• W3134524077 hasIssue "2" @default.
• W3134524077 hasLocation W31345240771 @default.
• W3134524077 hasLocation W31345240772 @default.
• W3134524077 hasOpenAccess W3134524077 @default.
• W3134524077 hasPrimaryLocation W31345240771 @default.
• W3134524077 hasRelatedWork W1535771998 @default.
• W3134524077 hasRelatedWork W1963931039 @default.
• W3134524077 hasRelatedWork W1967416111 @default.
• W3134524077 hasRelatedWork W1974879835 @default.
• W3134524077 hasRelatedWork W1983155011 @default.
• W3134524077 hasRelatedWork W2012654321 @default.
• W3134524077 hasRelatedWork W2941951683 @default.
• W3134524077 hasRelatedWork W3037440894 @default.
• W3134524077 hasRelatedWork W3179128638 @default.
• W3134524077 hasRelatedWork W4235834539 @default.
• W3134524077 hasVolume "9" @default.
• W3134524077 isParatext "false" @default.
• W3134524077 isRetracted "false" @default.
• W3134524077 magId "3134524077" @default.
• W3134524077 workType "article" @default.